^
    Back
    Association details:
    Biomarker:FLT3 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    azacitidine (DNMT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Blood
    Title:

    Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

    Published date:
    11/05/2020
    Excerpt:
    Ven+Aza compared to Aza monotherapy resulted in significantly higher CR+CRh rates among treatment-naïve pts with FLT3mut ineligible for intensive chemotherapy.
    DOI:
    10.1182/blood-2020-134100
    Trial ID:
    Viale-a